A prospective phase II randomized study of deferasirox to prevent iatrogenic iron overload in patients undertaking induction/consolidation chemotherapy for acute myeloid leukaemia.
Kennedy, Glen A. 1,2; Morris, Kirk L. 1; Subramonpillai, Elango 1; Curley, Cameron 1; Butler, Jason 1; Durrant, Simon 1
[Article] British Journal of Haematology. 161(6):794-801, June 2013.

(Format: HTML, PDF)